Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.70 | N/A | +6.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $4.70 | N/A | +6.17% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism about future growth. They pointed to strong product performance while recognizing market challenges.
Management highlighted strong performance in key therapeutic areas.
They acknowledged ongoing challenges in the market but expressed confidence in their pipeline.
The team emphasized their commitment to innovation and patient access.
Amgen's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 1.16%, likely due to the lack of revenue data and guidance, which may have left investors uncertain about future performance. The cautious tone from management may have also contributed to the stock's decline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
Oct 31, 2022